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Abstract
Background: Acute administration of the oral 5-HT1A receptor agonist buspirone, which is commonly used as an
anxiolytic drug, may improve compromised lower esophageal sphincter function. In an open-label trial we assessed
the effects of buspirone on esophageal motor function and symptoms in patients with esophageal involvement
associated with systemic sclerosis (SSc).
Methods: Thirty consecutive patients with SSc and symptomatic esophageal involvement, despite treatment with
proton pump inhibitors, underwent high resolution manometry and chest computed tomography for assessment
of motor function and esophageal dilatation, respectively. Regurgitation, heartburn, dysphagia, and chest pain
severity was subjectively scored by visual analog scales. Manometric parameters (primary endpoint) and symptom
severity (secondary endpoint) were re-examined after 4-week daily administration of 20 mg buspirone. Other
medications remained unchanged.
Results: Eight patients did not complete the trial because of buspirone-associated dizziness (n = 2), or nausea (n = 2),
or reluctancy to undergo final manometry. In the remaining 22 patients lower esophageal sphincter (LES) resting
pressure increased from 7.7 ± 3.9 to 12.2 ± 4.6 mmHg (p = 0.00002) after buspirone administration; other manometric
parameters did not change. Statistical analysis revealed negative correlation between individual increases in resting LES
pressure and supra-aortic esophageal diameter (r = -0.589, p = 0.017), suggesting a more beneficial effect in patients
with less severely affected esophageal function. Heartburn and regurgitation scores decreased at 4 weeks compared to
baseline (p = 0.001, and p = 0.022, respectively).
Conclusion: Our findings warrant more conclusive evaluation with a double-blind controlled study; however,
buspirone could potentially be given under observation for objective improvement in all patients with SSc who report
reflux symptoms despite undergoing standard treatment.
Trial registration: ClinicalTrials.gov Identifier: NCT02363478 Registered: 21-02-2014.
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Background
Systemic sclerosis (SSc) is a chronic autoimmune fibrotic
disease affecting the skin and other organs including the
gastrointestinal tract. The esophagus is commonly af-
fected in SSc and esophageal function is compromised
in up to 90 % of patients [1, 2]. Symptoms of esophageal
disease are due to gastroesophageal reflux disease
(GERD) and esophageal motor dysfunction. Thus, heart-
burn, regurgitation and dysphagia have been reported by
80 % of patients with SSc [3, 4].
Although several medications are used in patients with
symptomatic SSc and esophageal involvement, there is
no universally effective treatment. The current thera-
peutic approach includes administration of proton pump
inhibitors (PPIs) and prokinetics agents (including meto-
clopromide, erythromycin, cisapride and domperidone),
although the evidence to support their use is limited [5].
It is well-known that there are many issues in the effi-
cacy and long-term use of the currently available proki-
netic drugs; use of metoclopromide or erythromycin or
cisapride is restricted due to safety profile issues and ad-
ministration route problems, while administration of
domperidone has no effect on esophageal motor dys-
function in patients with symptomatic SSc [6].
Animal studies have identified serotonin (5-hydroxy-
tryptamine, 5-HT) as one of the putative neurotransmit-
ters involved in esophageal motor function making its
receptors suitable therapeutic targets [7]. Studies in
healthy volunteers show that acute administration of
buspirone, a 5-HT1A receptor agonist, has a strong
stimulatory effect on esophageal peristalsis and lower
esophageal sphincter (LES) function [8, 9]. Moreover, we
have recently observed that acute administration of bus-
pirone exerts a beneficial effect on esophageal motor
dysfunction associated with SSc [6]. Thus, in order to in-
vestigate whether buspirone exerts a long-term effect in
SSc-associated esophageal involvement we conducted a
prospective 4-week open-label trial. The primary object-
ive was to assess the efficacy of buspirone on LES dys-
function. The secondary efficacy endpoint was change in
esophageal symptoms after buspirone administration.
Methods
Study population
Thirty consecutive consenting patients who fulfilled classifi-
cation criteria for SSc [10] and were able to perform high
resolution manometry (HRM) participated in this open-
label, non-randomized study. The only inclusion criterion
was the presence of symptoms associated with esophageal
involvement, such as regurgitation, heartburn, dysphagia,
and chest pain, despite standard treatment with PPIs. These
symptoms were scored on a 100-point visual analog scale
(VAS) ranging from 0 (absent) to 100 (very severe)..Other
types of esophageal diseases that could explain patients’
symptoms were excluded because all patients had under-
gone gastroscopy in the past.
Eight patients did not complete the study; 4 patients re-
ported adverse effects with buspirone administration (2
dizziness and 2 nausea) and 4 patients were reluctant to
perform the second HRM examination. The remaining 22
patients (aged 52.5 ± 11.6 years, 19 women) were re-
examined after 4 weeks. During the study period all
patients continued their therapy unchanged, including ad-
ministration of proton pump inhibitors. All patients were
on single PPIs dose before and during the study period
and none was on medications that could affect results,
such as prokinetics or erythromycin.
Before proceeding to esophageal manometry studies all
patients filled out a self-reported symptom questionnaire
in order to assess the severity of esophageal symptoms.
Severity of dysphagia, heartburn, regurgitation, and chest
pain was measured on a VAS (0–100). The VAS score has
been adopted in many other trials for evaluation of vis-
ceral symptoms and has been used as a tool for self-
assessment of symptoms [11, 12], and any decrease in the
score at week 4 versus baseline was considered an im-
provement. Demographic data and phenotypic character-
istics of the disease were collected from the clinical charts.
Moreover, in all patients the supra-aortic and infra-aortic
coronal diameters of the esophagus were measured in
chest computed tomography (CT) performed within the
previous 3 months. Esophageal dilatation was deemed
present when the diameter was >9 mm [13]. The study
protocol was approved by the ethics committee of
“Laikon” General Hospital and informed consent was ob-
tained from all participating patients.
High resolution manometry
All patients were fasted and were studied in the supine
position. Esophageal manometry was performed with a
water-perfused assembly with 22 pressure sensors (Solar
GI HRM, MMS, Enschede, The Netherlands). The HRM
catheter was passed trans-nasally and positioned to rec-
ord from the hypopharynx to the stomach. The catheter
was fixed in place by taping it to the nose. The mano-
metric examination included a 30-sec period to assess
basal LES pressure and 10 swallows of 5 mL water.
Double swallows were discarded and these were re-
peated. The study was repeated 4 weeks after oral admin-
istration of 20 mg buspirone (10 mg twice a day). We
recorded 1) amplitude, duration and velocity of contrac-
tions at the distal part of the esophagus (defined as the
mean amplitude at 3 and 8 cm proximal to the LES upper
border of the esophagus) and 2) resting and residual LES
pressure and integrated relaxation pressure (IRP). The
LES pressures were referenced to intragastric pressure
and we reported the mean resting pressure values.
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All HRM tracings were interpreted by the same inves-
tigator (GK), who was blinded to whether administration
of buspirone was performed. Hypotensive LES was con-
sidered when LES resting pressure was ≤10 mmHg,
whereas isobaric contour <20 mmHg was considered as
the cutoff for esophageal hypomotility [14].
Statistical methods
The paired-sample t test was used to compare changes
from baseline in manometric values and severity of
symptoms after buspirone administration, as all data an-
alyzed were normally distributed. The Spearman correl-
ation coefficient was used to assess the relationship
between increase in LES pressure and other clinical,
manometric, and CT parameters, because of non-
canonical data distribution. Values were expressed as
mean ± SD. A p value <0.05 was considered significant.
Results
Table 1 summarizes demographic characteristics, expres-
sion and duration of disease, CT, baseline manometry,
and severity of esophageal symptoms. The mean ampli-
tude of distal esophageal contractions was 16.6 ± 9.6
mmHg, whereas esophageal hypomotility was identified
in 19 patients (86 %). The mean resting pressure of the
LES was 7.7 ± 3.9 mmHg, whereas a hypotensive LES
was observed in 17 patients (77 %). Both esophageal
body and LES abnormalities were found in 16 patients
(73 %). According to the Chicago classification 16 pa-
tients had absent peristalsis, 5 patients had weak peri-
stalsis and 1 patient had normal esophageal motility. On
chest CT 12 patients (54.5 %) had supra-aortic esopha-
geal dilatation, whereas almost all patients had infra-
aortic esophageal dilatation (21/22, 95.5 %).
Heartburn and regurgitation were reported by almost all
patients (91 % and 86 %, respectively), while dysphagia
was reported by 54.5 % of patients. Only 36 % of patients
reported chest pain as one of their symptoms. Moreover,
regurgitation and heartburn were the most bothersome
symptoms reported to a similar extent, followed by dys-
phagia and chest pain (Table 1).
Effect of buspirone on manometric parameters
Following buspirone administration for 4 weeks the LES
resting pressure significantly increased from 7.7 ± 3.9 to
12.2 ± 4.6 mmHg (p < 0.00005). Figure 1 increased LES rest-
ing pressure after buspirone administration was observed in
15 patients (68 %) with a range of 4–13 mmHg (41–220 %,
accordingly). There were significantly fewer patients with
hypotensive LES after compared to before buspirone ad-
ministration (8/22 vs. 17/22, respectively, p = 0.006).
In contrast to LES resting pressure, buspirone admin-
istration had no effect on LES residual pressure or on
IRP (Table 2). In addition, buspirone administration did
not increase the duration and velocity of esophageal
body contractions or the amplitude of contractions,
compared to baseline values (Table 2). Buspirone was
well-tolerated by all patients who completed the study.
Correlation between individual increase in LES pressure
and other clinical, manometric and CT parameters
Table 3 summarizes the correlation between individual
increase in LES pressure and other variables. There was
moderate, but significant, inverse correlation between
increased LES resting pressure and supra-aortic diameter
Table 1 Demographic characteristics, disease characteristics,
symptoms, and manometry in the study population (n = 22)
Variable Value
Age (years) 52. 5 ± 11.9
Sex (female/male) 19/3
Duration of disease (years)a 8.7 ± 6.7
Diffuse SSc (n (%)) 16 (72.7)
Pulmonary fibrosisb 15 (68.1)
Digital ulcersc 10 (45.5)
Anti-Scl 70 (%) 9 (41 %)
ANA (%) 19 (86.4 %)
ACA (%) 2 (9.1 %)
CPK (> × 2 normal values) (%) 2 (9.1 %)d
Supra-aortic coronal diameters (cm) 12.4 ± 5.3
Infra-aortic coronal diameters (cm) 22.5 ± 11.1




-chest pain 8 (36.4)
severity of symptoms (0–100)
-dysphagia 25.8 ± 30.7
-heartburn 27.1 ± 24.0
-regurgitation 39.3 ± 29.8
-chest pain 10.4 ± 2.1
amplitude of distal contractions (mmHg) 16.6 ± 9.6
duration of distal contractions (cm) 3.7 ± 2.4
velocity of distal contractions (cm/sec) 2.6 ± 1.9
LES resting pressure (mmHg) 7.7 ± 3.9
LES residual pressure (mmHg) 2.9 ± 1.9
IRP (mmHg) 3.1 ± 2.3
SSc systemic sclerosis, ANA antinuclear antibody, ACA anti-centromere anti-
body, LES lower esophageal sphincter, IRP integrated relaxation pressure, HRCT,
High resolution computed tomography, CPK, creatinophosphokinase, anti-Scl,
anti-topoisomerase I
aDisease duration was from first non-Raunaud’s symptom
bPresence of interstitial lung disease was determined after evaluation of HRCT
cFive out of these ten patients had active digital ulcers at the time of the manometry
dNone of the patients had clinical signs of myositis or skeletal myopathy
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(p = 0.017). The Pearson correlation coefficient was an r
value of -0.589. In patients without supra-esophageal
dilatation there was greater improvement in LES pres-
sure (83.9 ± 38.1 % vs.19.2 ± 26.8 %, p = 0.037). There
was no significant correlation between increased LES
pressure and other measured parameters.
Effect of buspirone on esophageal symptoms
The severity of regurgitation and heartburn significantly
decreased from baseline following buspirone administra-
tion for 4 weeks (39.3 ± 29.8 vs. 24.4 ± 22.0, p = 0.02 and
37.1 ± 23.9 vs. 21.9 ± 21.2, p = 0.001, respectively). There
was no significant improvement in the scores for severity
of chest pain and dysphagia (10.4 ± 23.1 vs. 8.5 ± 20.0
and 25.8 ± 30.7 vs. 18.9 ± 21.9, p = 0.203, respectively).
Improvement in the severity of heartburn was reported
by 70 % (14/20) of patients who had heartburn at base-
line, while 58 % (11/19) of patients with regurgitation at
baseline had improvement in the severity of regurgita-
tion. Increased LES resting pressure was simultaneously
observed in the majority of patients with improvement
in heartburn and regurgitation (12/14 and 8/11, respect-
ively). Half of the patients with baseline dysphagia re-
ported improvement in their symptom severity, while a
minority of patients (25 %) with baseline chest pain had
an improvement in the severity of their symptoms.
Discussion
Treatment of patients with symptomatic SSc and
esophageal involvement is still an area of unmet need, as
there is no available treatment with established efficacy.
Administration of PPIs and prokinetic drugs do not ap-
pear to provide substantial symptomatic relief in patients
with SSc and esophageal symptoms [5]. Pathophysiology
of gastrointestinal dysmotility in SSc is multifactorial
and different neurotransmitters could be involved in this
process [15, 16]. Serotonin (5-HT) is considered a key
neurotransmitter and acute studies, both in healthy sub-
jects and patients with SSc, have shown that agonists of
specific class of its receptors, such as 5-HT1A, could be
a putative therapeutic option [6, 8, 9]. Buspirone had
been initially developed for clinical use in the treatment
of depression and anxiety disorders. Its mechanisms of
action are thought to include agonistic actions, mainly
on 5-HT1A receptors, but also on dopamine D2 recep-
tors. Buspirone is absorbed rapidly and almost com-
pletely with a tmax = 0.89 ± 0.15 h [17].
To the best of our knowledge no previous study has pro-
spectively investigated whether a pharmaceutical agent may
help patients with SSc and esophageal involvement. The re-
sults of our open-label, prospective 4-week trial suggest that
the 5-HT1A receptor agonist, buspirone, given orally for 4
weeks, significantly increases the LES resting pressure by 41
% to 220 % over the baseline values in almost 70 % of pa-
tients with SSc. Furthermore, patients with a less dilated
esophagus as detected on chest CT had a better response
to buspirone administration. This is an important aspect of
our study, as patients with SSc undergo routine chest CT as
a screening test for lung fibrosis. Many studies have sug-
gested that measurement of esophageal coronal diameter
on chest CT is a marker of the functional status of the
esophagus in SSc and a dilated esophagus represents more
severe visceral involvement [18, 19].
Table 2 Manometric parameters at baseline and after 4-week
daily administration of 20 mg buspirone
Baseline After buspirone p
Amplitude (mmHg) 16.6 ± 9.6 17.5 ± 9.6 0.163
Velocity (cm/sec) 3.7 ± 2.4 3.4 ± 1.9 0.701
Duration (sec) 2.6 ± 1.9 3.1 ± 2.3 0.668
LES resting pressure (mmHg) 7.7 ± 3.9 12.2 ± 4.6 0.00002
LES residual pressure (mmHg) 2.9 ± 1.9 3.2 ± 2.1 0.157
IRP (mmHg) 3.1 ± 2.3 3.5 ± 2.1 0.143
LES lower esophageal sphincter, IRP integrated relaxation pressure
Table 3 Correlation between increase in LES pressure after 4-week
daily administration of 20 mg buspirone and clinical, manometric
and computed tomography parameters
r p
Baseline LES -0.356 0.113
Supra-aortic diameter -0,589 0.017
Infra- aortic diameter -0.406 0.191
Disease duration -0.226 0.325
Heartburn 0.129 0.578
Regurgitation -0.188 0.415
Chest pain 0.103 0.657
Dysphagia 0.188 0.414






















baseline at week 4
Fig. 1 Change in lower esophageal sphincter (LES) pressure in each
individual at baseline and after 4-week daily oral administration of
20 mg buspirone
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Herein, the 4-week administration of buspirone also
alleviated heartburn and regurgitation in the majority of
patients. Buspirone seems more effective for GERD-
related symptoms, whereas symptoms related to esopha-
geal hypomotility, such as dysphagia and chest pain are
not affected. Thus, we could suggest that buspirone ad-
ministration may be most helpful for the subgroup of
SSc patients with reflux symptoms. An objective assess-
ment of reflux response with pH-impedance measure-
ment could certainly enhance our results.
As all patients were on PPIs before and during the
study period, the strategy with add-on buspirone could
be a worthwhile therapeutic option. Keeping in mind the
anecdotal evidence that persistent reflux contributes sig-
nificantly to the development of interstitial lung disease
and/or progress, which is the leading cause of death in
SSc, the potential beneficial effect of buspirone becomes
more important. Buspirone-associated improvement in
the severity of reflux symptoms can be explained by a
strong stimulatory effect on LES resting pressure. How-
ever, other mechanisms cannot be excluded. Comorbid
psychiatric diseases in patients with a chronic disorder,
such as SSc, and especially anxiety, are common [20, 21].
Buspirone is used as anxiolytic drug in clinical practice.
Therefore, a potential alteration in the sensitivity by de-
creasing the anxiety level may play a role in symptom im-
provement. As we did not include measurement of
anxiety scores, this is a limitation of the present study.
However, in the event that the main mechanism under-
lying symptom improvement with buspirone was the
anxiolytic effect of the drug, other non-reflux symptoms
should have been improved.
A limitation of the present study, due to restrictive
regulatory rules that we were unable to overcome, is that
it is not a randomized, placebo-controlled investigation
and there is a lack of a control arm. Another limitation
is the relatively small number of patients studied; how-
ever, we have to keep in mind that patients with SSc due
to the chronic nature of their disease have several med-
ical disabilities, making recruitment very challenging.
The use of a validated questionnaire, such as the UCLA
STCC SSc-GI [22] rather than a self-reported one could
strengthen our results, however, this questionnaire,
which covers a broad spectrum of gastrointestinal symp-
toms in patients with SSc, is not validated in Greek.
Moreover, the majority of available questionnaires are
focused on reflux symptoms rather than on dysmotility-
associated symptoms characterizing SSc.
Buspirone was well-tolerated in the present study.
Treatment interruption due to adverse effects (dizziness
and nausea) was observed in only 4 out of 30 patients.
Patients who completed the study reported sporadic and
self-limited adverse effects that did not affect their daily
activities.
Conclusions
In conclusion, our study showed that 4-week daily ad-
ministration of buspirone increases the LES resting pres-
sure and improves esophageal symptoms in the majority
of SSc patients with esophageal involvement. Further-
more, buspirone exerts a greater beneficial effect on
patients with less severely affected esophageal function
as detected on chest CT, suggesting a therapeutic role
mainly in patients with earlier or less severe involve-
ment. Although further evaluation in placebo-controlled
studies is warranted, buspirone could potentially be
given under observation for objective improvement in all
patients with SSc who report reflux symptoms, despite
undergoing standard treatment.
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